Enhancing Biomarker Detection in Cancer: A Comparative Analysis of Preanalytical Reverse Transcription Enzymes for Liquid Biopsy Application

• Published in: Laboratory investigation Vol. 104; no. 10; p. 102142
• Main Authors: Wüstmann, Neele, Humberg, Verena, Vieler, Julia, Seitzer, Konstantin, von Rüden, Sabine, Juratli, Mazen A., Pascher, Andreas, Kemper, Marcel, Bleckmann, Annalen, Franken, André, Neubauer, Hans, Fehm, Tanja N., Bögemann, Martin, Schlack, Katrin, Schrader, Andres Jan, Bernemann, Christof
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-10-2024
• Subjects: biomarker; circulating tumor cells; liquid biopsy; metastatic cancer; methodology; reverse transcriptase; sensitivity; reverse transcriptase; metastatic cancer; sensitivity; biomarker; circulating tumor cells; liquid biopsy; methodology
• ISSN: 0023-6837; 1530-0307; 1530-0307
• DOI: 10.1016/j.labinv.2024.102142

Circulating tumor cells and liquid biopsy-based biomarkers might one day play a crucial role in the treatment decision process for patients of several cancer entities. However, clinical studies on liquid biopsy approaches revealed distinct detection rates and thus, different risk scoring for patients. This study delves into the comparison of 2 utilized reverse transcription enzymes, namely, SuperScript IV VILO (VILO) and Sensiscript (SS), aiming to understand their impact on biomarker detection rates. Prostate cancer cell lines were used to assess detection limits, followed by an investigation of biomarker status in clinical liquid biopsy samples of distinct tumor entities. Our findings highlight the superior reverse transcription efficacy of VILO over SS, commonly used in studies employing the AdnaTest platform. The enhanced efficacy of VILO results in a significantly higher number of patients positive for biomarkers. Clinically, the use of a less-sensitive enzyme system may lead to the misclassification of genuinely biomarker-positive patients, potentially altering their prognosis due to inadequate clinical monitoring or inappropriate treatment strategies.